[Translation] A single-dose, randomized, open-label, two-period, two-sequence, crossover bioequivalence study of famciclovir tablets in healthy subjects under fasting and fed conditions

主要研究目的 1.研究空腹状态下单次口服受试制剂泛昔洛韦片（规格：250 mg，华益药业科技（安徽）有限公司生产，杭州沐源生物医药科技有限公司提供）与参比制剂泛昔洛韦片（商品名：Famvir，规格：250 mg，Novartis）在健康成年受试者体内的药代动力学，评价两制剂生物等效性。 2.研究餐后状态下单次口服受试制剂泛昔洛韦片（规格：250 mg，华益药业科技（安徽）有限公司生产，杭州沐源生物医药科技有限公司提供）与参比制剂泛昔洛韦片（商品名：Famvir，规格：250 mg，Novartis）在健康成年受试者体内的药代动力学，评价两制剂生物等效性。次要研究目的评价健康受试者空腹和餐后单次口服受试制剂（T）泛昔洛韦片和参比制剂（R）泛昔洛韦片（Famvir）后的安全性。

[Translation]

Main study objectives 1. To study the pharmacokinetics of the test preparation famciclovir tablets (specification: 250 mg, produced by Huayi Pharmaceutical Technology (Anhui) Co., Ltd., provided by Hangzhou Muyuan Biopharmaceutical Technology Co., Ltd.) and the reference preparation famciclovir tablets (trade name: Famvir, specification: 250 mg, Novartis) in healthy adult subjects after a single oral administration in the fasting state, and to evaluate the bioequivalence of the two preparations. 2. To study the pharmacokinetics of the test preparation famciclovir tablets (specification: 250 mg, produced by Huayi Pharmaceutical Technology (Anhui) Co., Ltd., provided by Hangzhou Muyuan Biopharmaceutical Technology Co., Ltd.) and the reference preparation famciclovir tablets (trade name: Famvir, specification: 250 mg, Novartis) in healthy adult subjects after a single oral administration in the fed state, and to evaluate the bioequivalence of the two preparations. Secondary study objectives To evaluate the safety of the test preparation (T) famciclovir tablets and the reference preparation (R) famciclovir tablets (Famvir) after a single oral administration in healthy subjects after fasting and feeding.

Start Date25 May 2022

Sponsor / Collaborator

Hangzhou Muyuan Biomedical Technology Co., Ltd.

ChiCTR2100048785 / SuspendedNot ApplicableIIT

Evaluation of the effect of famciclovir anti-Epstein-Barr virus therapy on surgical treatment of patients with myasthenia gravis and thymic hyperplasia

Start Date01 Aug 2021

Sponsor / Collaborator-

ChiCTR2100049088 / SuspendedNot ApplicableIIT

Evaluation of the effect of famciclovir anti-Epstein-Barr virus therapy on surgical treatment of patients with thymoma complicated with myasthenia gravis

Start Date01 Aug 2021

Sponsor / Collaborator-

100 Clinical Results associated with Famciclovir

100 Translational Medicine associated with Famciclovir

100 Patents (Medical) associated with Famciclovir

1,149

Literatures (Medical) associated with Famciclovir

01 Aug 2024·Comparative Immunology, Microbiology and Infectious Diseases

Viral pathogens in domestic cats in southern Italy: A retrospective analysis in Sicily, 2020–2022

Article

Author: Di Pietro, Simona ; Vicari, Domenico ; Giudice, Elisabetta ; Gucciardi, Francesca ; Guercio, Annalisa ; Mira, Francesco ; Schirò, Giorgia ; Purpari, Giuseppa ; Talarico, Virginia ; Antoci, Francesco ; Origgi, Francesco ; Geraci, Francesco

A retrospective study was carried out on selected feline viral pathogens detected in domestic cat in Sicily, southern Italy. Samples from 64 cats, collected from 2020 to 2022, were analysed for the presence of feline panleukopenia virus, canine parvovirus type 2 (CPV-2), feline coronavirus (FCoV), feline calicivirus (FCV), feline herpesvirus type 1, norovirus (NoV), and rotavirus (RoV). Single (45 %) or mixed (38 %) viral infections were detected. FPV, related with other Italian FPV strains, remains the main viral cause of infection (66 %). CPV-2c Asian lineage strains (3 %) were detected for the first time in domestic cats in Europe. FCoV (29.6 %), either enteric or systemic, and systemic FCV (18.7 %) infections were detected in positive cats. Less commonly reported viruses (GIV.2/GVI.2 NoVs, RoV), potentially related to the animal/human interface, were detected at lower rates as well (5 %). The present epidemiological data suggest the need to improve disease prevention, immunization, and biosecurity strategies.

01 Jul 2024·Veterinary Ophthalmology

Detection of Mycoplasma spp. and feline calicivirus in cats with ocular surface disease

Article

Author: Zhu, Xiaojuan ; Lewin, Andrew C

AbstractObjectiveTo survey the prevalence of pathogens in shelter‐housed cats with active ocular surface disease (OSD).Animals StudiedA total of 255 shelter‐housed domestic cats with evidence of active OSD. No normal, unaffected cats were sampled.Procedure(s)OSD scoring was performed on cats with active OSD. Combined oropharyngeal/conjunctival swabs were submitted for rt‐PCR/PCR for feline herpesvirus (FHV‐1), feline calicivirus (FCV), Chlamydia spp. (CHL), Bordetella bronchiseptica (BORD), and Mycoplasma spp. (MYC).ResultsPathogens were detected as follows: 76.4% (195/255) MYC, 57.6% (147/255) FHV‐1, 42.7% (109/255) FCV, 26.7% (68/255) CHL, and 5.5% (14/255) BORD. Monoinfections affected 21.1% (54/255) animals, with MYC being the most common monoinfection (12.5%, 32/255), followed by FHV‐1 (4.7%, 12/255), followed by CHL (2.4%, 6/255), followed by FCV (1.6%, 4/255), with no animals having a BORD monoinfection. Dual infections affected 36.4% of animals (93/255), with MYC detected in 30.1% (77/255) dual infections and FCV detected in 12.9% (33/255) dual infections. Dual infections with MYC and FCV together were detected in 9.8% (25/255) animals. Many animals (35.3%, 90/255) were found to be affected by 3 or more pathogens, and 7.1% (18/255) animals had no pathogens detected. OSD scores were not influenced by any variable assessed, including the number and type of pathogens detected.ConclusionMYC, FHV‐1, FCV, and CHL were commonly detected in this group of animals with OSD. Both MYC and FCV (alone or in combination with each other) were detected in multiple animals with active OSD, supporting prior evidence that either may independently act as a primary ocular surface pathogen.

18 Jun 2024·Applied and Environmental Microbiology

Efficacy of three EPA-registered antimicrobials and steam against two human norovirus surrogates on nylon carpets with two backing types

Article

Author: Jiang, Xiuping ; Fraser, Angela ; Huang, Jinge

ABSTRACT Carpet cleaning guidelines currently do not include the use of an antimicrobial, except after a bodily fluid event. To address this gap, we compared the efficacy of three antimicrobials—two hydrogen peroxide-based (H 2 O 2 ) products (A and B) and one chlorine-based product (C)—and a steam treatment against two norovirus surrogates, specifically feline calicivirus (FCV) and Tulane virus (TuV). These tests were performed on nylon carpets with either water-permeable or waterproof backing types. The effect of repeated antimicrobial use on carpet properties was also evaluated. For a carpet with water-permeable backing, products A, B, and C achieved a 0.8, 3.1, and 0.9 log 10 PFU/coupon reduction of FCV and 0.3, 2.5, and 0.4 log 10 TCID 50 /coupon reduction of TuV, respectively, following a 30 min contact time. For carpet with waterproof backing, only product B achieved a 5.0 log 10 PFU/coupon reduction of FCV and >3.0 log 10 TCID 50 /coupon reduction of TuV, whereas products A and C achieved a 2.4 and 1.6 log 10 PFU/coupon reduction of FCV and a 1.2 and 1.2 log 10 TCID 50 /coupon reduction of TuV, respectively. Steam treatment achieved a ≥ 5.2 log 10 PFU/coupon reduction of FCV and a > 3.2 log 10 TCID 50 /coupon reduction of TuV in 15 seconds on the carpet with both backing types. The repeated use of products A and B decreased the tensile strength of the carpet backing, while use of product B resulted in cracks on carpet fibers. Overall, steam treatment for 15 seconds was efficacious on both carpet types, but only product B achieved efficacy after a 30-minute exposure on the carpet with waterproof backing. IMPORTANCECarpets are common in long-term care facilities, despite its potential as a vehicle for transmission of agents associated with healthcare-associated infections, including human norovirus (NoV). Presently, our understanding of carpet disinfection is limited; hence, there are no commercial antimicrobials against norovirus available for use on carpets. Our findings showed that steam treatment, which minimally affected the properties of carpet fibers and backing, was more efficacious against human norovirus surrogates on carpets compared to the three chemical antimicrobials tested. Additionally, the two surrogates were more sensitive to chemical antimicrobials on the carpet with waterproof backing compared to carpets with water-permeable backing. These findings can inform development of antimicrobials for use on carpets contaminated with human norovirus.

News (Medical) associated with Famciclovir

08 Aug 2024

·www.globenewswire.com

Virios Therapeutics Announces Second Quarter 2024 Financial Results

- Bateman Horne Center completed enrollment in its groundbreaking investigator-initiated Long-COVID phase 2a study featuring valacyclovir and celecoxib (IMC-2) - - Top-line results from the Bateman Horne Center’s Long-COVID phase 2a study expected in October 2024, will provide key insights into final design of planned Phase 2b study - ATLANTA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced financial results for the second quarter ended June 30, 2024. Key Highlights Completion of enrollment in the BHC-202 3-arm study, which is comparing two dose levels of the valacyclovir/celecoxib combination vs placebo over 12 weeks to treat symptoms of LC. BHC-202 is being conducted by the Bateman Horne Center under an unrestricted investigational grant provided by the Company. Top line results are expected in October 2024.Ongoing blinded safety analysis of the BHC-202 study indicates that study drug (either the combination of valacyclovir and celecoxib or matching placebo) has been very well tolerated to date with no serious adverse events reported, and only a few transient treatment emergent adverse events being reported.The Company completed a public offering with gross proceeds of $1.7 million to extend operational runway into Q1 2025.The Company continues to actively explore opportunities that will build shareholder value through strategic partnerships, collaborations or other transactions. “Epidemiologic research highlights that acute COVID-19 infections continue to outnumber flu cases and leads to higher levels of hospitalization and death” said R. Michael Gendreau, MD, Chief Medical Officer of Virios Therapeutics. “A recent study published in the New England Journal of Medicine highlights that Long-COVID sequelae still represents a significant unmet medical need, with unvaccinated patients more than twice as likely to develop Long-COVID following an acute infection. Decreasing vaccination rates suggest this unmet medical need will persist for the foreseeable future.” Second Quarter 2024 Financial Results Research and development expenses for the second quarter of 2024 were $0.3 million, compared to $0.6 million for the second quarter of 2023. The quarter-over-quarter change was primarily due to decreases in expenses for drug development and manufacturing of $0.2 million. General and administrative expenses for the second quarter of 2024 were $0.7 million, compared to $0.9 million for the second quarter of 2023. The quarter over quarter change was primarily due to a decrease in insurance expenses associated with being a public company of $0.1 million and a decrease in accounting and legal fees of $0.1 million. Net loss for the second quarter of 2024 was $1.0 million, or $0.05 basic and diluted net loss per share, compared to a net loss of $1.4 million, or $0.08 basic and diluted net loss per share, for the second quarter of 2023. As of June 30, 2024, Virios Therapeutics’ cash totaled $3.0 million. The Company believes it will have sufficient resources to fund operations into the first quarter of 2025. About Virios Therapeutics Virios Therapeutics (Nasdaq: VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia (“FM”) and Long-COVID (“LC”). Overactive immune response related to activation of tissue resident herpesvirus has been postulated to be a potential root cause of chronic illnesses such as FM, irritable bowel syndrome, LC, chronic fatigue syndrome and functional somatic syndromes, all of which are characterized by a waxing and waning manifestation of disease, often triggered by events which compromise the immune system. The Company’s lead development candidates are novel, proprietary, fixed dose combinations of an antiviral compound and celecoxib designed to synergistically suppress herpesvirus replication, with the end goal of reducing virally promoted disease symptoms. IMC-1 (fixed dosage combination of famciclovir and celecoxib) has been granted fast track designation by the FDA. For more information, please visit www.virios.com. Follow Virios Therapeutics Email Alerts: https://ir.virios.com/resources/email-alerts LinkedIn: https://www.linkedin.com/company/viriosbiotech/ Twitter: https://twitter.com/ViriosBiotech Facebook: https://www.facebook.com/ViriosBiotech/ Forward-Looking Statements Statements in this press release contain “forward-looking statements,” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” "will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Virios Therapeutics’ current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the completion, timing and results of current and future clinical studies relating to Virios Therapeutics’ product candidates. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Amended Annual Report on Form 10-K/A for the year ended December 31, 2023, filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Virios Therapeutics, Inc. undertakes no duty to update such information except as required under applicable law. Contact: IR@Virios.com -Financial Tables Follow- VIRIOS THERAPEUTICSSelected Financial Data (unaudited) Condensed Statements of Operations Data Three Months EndedJune 30, Six Months EndedJune 30, 2024 2023 2024 2023 Revenue $— $— $— $— Operating expenses: Research and development 336,084 557,843 679,801 1,055,557 General and administrative 733,740 919,374 1,704,124 1,978,947 Total operating expenses 1,069,824 1,477,217 2,383,925 3,034,504 Loss from operations (1,069,824) (1,477,217) (2,383,925) (3,034,504)Other income 19,991 36,313 42,757 76,736 Net loss $(1,049,833) $(1,440,904) $(2,341,168) $(2,957,768)Net loss per share of common stock — basic and diluted $(0.05) $(0. 08) $(0.11) $(0.16)Weighted average shares outstanding — basic and diluted 22,900,794 18,411,399 21,079,366 18,371,118 Condensed Balance Sheet DataJune 30, December 31, 2024 2023 Cash$3,020,183 $3,316,946 Total assets 3,635,889 4,165,442 Total liabilities 500,076 358,548 Total stockholders’ equity 3,135,813 3,806,894 Source: Virios Therapeutics, Inc.

Financial StatementPhase 2Fast Track

06 Aug 2024

·www.fiercepharma.com

Novartis and Viatris sued by estate of Henrietta Lacks, whose cells were extracted for research in 1951

A statue of Henrietta Lacks is the first public sculpture of a Black woman made by a Black woman in the U.K. Lacks' cancer cells changed the course of modern medicine after they were taken from her without her consent or knowledge in 1951. Lacks' estate has sued four biopharma companies, including Novartis and Viatris on Monday, for allegedly profiting off discoveries made with Lacks' cells The family of a Baltimore woman whose cells were extracted for medical research without her consent more than 70 years ago has filed another lawsuit against drugmakers that allegedly profited from the discoveries they made using her genetic material.The family of Henrietta Lacks has sued Novartis and Viatris, seeking a jury trial and the “full amount” of profits obtained through their use of the “stolen” cells, according to the lawsuit, which was filed Monday in federal court in Baltimore.“Medical research has a long, troubled history of exploiting Black individuals, and Henrietta Lacks’s story is a stark reminder of this legacy,” Ben Crump, a civil rights attorney representing the family, said in a release. “It is time for these corporations to be held accountable for their unjust enrichment and to provide the Lacks family with the recognition and compensation they deserve.”The lawsuit is the third filed by the family against a pharma company. Last year, Thermo Fisher came to a settlement for an undisclosed sum. Days later, the Lacks’ estate filed a similar suit against Ultragenyx over its production of viral vectors.Novartis said that it doesn’t comment on litigation. Viatris did not respond to a request for comment.The lawsuits harken to an era when racism was rampant in the healthcare system. They also open difficult questions for courts to consider as Lacks’ case traces to 1951 when doctors didn’t need patients' permission to harvest their cells. Lacks was a young mother of three in Baltimore when she developed cervical cancer. Tissue taken from a biopsy—before she died that same year at age 31—was saved and became the first human cells to grow and reproduce in lab dishes. Dubbed HeLa cells, they became the first “immortal human cell line” and important building blocks for scientific studies around the world, leading to the discovery of the polio and COVID vaccines, breakthroughs in genetic mapping and scores of other medical innovations.While Johns Hopkins never profited from HeLa cells, companies and other research organizations have developed thousands of patents using HeLa cells. Novartis holds “hundreds” of those patents, according to the lawsuit.“Novartis has utilized Mrs. Lacks’s genetic material extensively as a fundamental component in their research and development processes,” the lawsuit reads. “By using these cells, Novartis can efficiently test and refine their pharmaceutical compounds, accelerating the development of new drugs.”Novartis and Viatris have always been aware of the origin of Lacks’ cells, according to the lawsuit. In a 2021 website posting, the company cited Lacks’ story in announcing an initiative to address health disparities through “holistic community-based collective action.”Among the products Novartis has developed using HeLa cells, according to the lawsuit, are herpes drug Famvir, CAR-T therapy Kymriah and gene therapy Zolgensma. Viatris treatments cited in the suit include the depression drug mirtazapine and herpes drug Denavir.

Cell TherapyPatent InfringementImmunotherapy

01 Aug 2024

·www.globenewswire.com

Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024

ATLANTA, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), announced today that it will report second quarter 2024 financial results on Thursday, August 8, 2024 before the open of the financial markets. About Virios Therapeutics Virios Therapeutics (Nasdaq: VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia (“FM”) and Long-COVID (“LC”). Overactive immune response related to activation of tissue resident herpesvirus has been postulated to be a potential root cause of chronic illnesses such as FM, irritable bowel syndrome, LC, chronic fatigue syndrome and functional somatic syndromes, all of which are characterized by a waxing and waning manifestation of disease, often triggered by events which compromise the immune system. The Company’s lead development candidates are novel, proprietary, fixed dose combinations of an antiviral compound and celecoxib designed to synergistically suppress herpesvirus replication, with the end goal of reducing virally promoted disease symptoms. IMC-1 (fixed dosage combination of famciclovir and celecoxib) has been granted fast track designation by the FDA. For more information, please visit www.virios.com. Follow Virios Therapeutics Email Alerts: https://ir.virios.com/resources/email-alerts LinkedIn: https://www.linkedin.com/company/viriosbiotech/ Twitter: https://twitter.com/ViriosBiotech Facebook: https://www.facebook.com/ViriosBiotech/ Forward-Looking Statements Statements in this press release contain “forward-looking statements,” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” "will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Virios Therapeutics’ current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the completion, timing and results of current and future clinical studies relating to Virios Therapeutics’ product candidates. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Amended Annual Report on Form 10-K/A for the year ended December 31, 2023, filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Virios Therapeutics, Inc. undertakes no duty to update such information except as required under applicable law. Contact: IR@Virios.com

Financial StatementFast TrackImmunotherapy

100 Deals associated with Famciclovir

External Link

KEGG	Wiki	ATC	Drug Bank
D00317	Famciclovir	S01AD07 J05AB09	DB00426

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Herpes Genitalis	-	Novartis Pharma AG	01 Jan 1993
Herpes Labialis	-	Novartis Pharma AG	01 Jan 1993
Herpes Zoster	-	Novartis Pharma AG	01 Jan 1993

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Herpes Genitalis	Preclinical	US	Novartis Pharmaceuticals Corp.	24 Dec 2009
Herpes Simplex	Preclinical	US	Novartis Pharmaceuticals Corp.	29 Jun 1994
Herpes Zoster	Preclinical	US	Novartis Pharmaceuticals Corp.	29 Jun 1994
Chickenpox	Discovery	PA	Novartis AG	01 Jul 2005
Chickenpox	Discovery	US	Novartis AG	01 Jul 2005
Chickenpox	Discovery	CR	Novartis AG	01 Jul 2005

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05283551 (ECTRIMS2023)	Phase 2	Multiple Sclerosis Epstein-Barr virus (EBV)	30	Famciclovir 500mg bd	qrqtzvxxhb(ikikhejuai) = vmcjszoppx uzdmtharac (mbdjlprcap )	-	30 Sep 2023
NCT00878072 (CTgov)	Phase 2/3	Herpes Labialis	53	Famciclovir	wdozeavnqi(zcyqhohila) = ufhjdgxozs ikkplxznvs (jqeucybpon, anusqctely - gdobfiziaw) View more	-	25 Jun 2021
NCT01526408 (Famvir, CTgov)	Phase 3	Meniere Disease	11	Placebo (Placebo Arm)	nrzzrzmrlo(ytpwoaveyr) = oodiqrraqy syqswuvxnw (vvyrkdcwop, mvfqliieit - elsmwozudi) View more	-	19 Apr 2021
				Famciclovir (Active Arm)	nrzzrzmrlo(ytpwoaveyr) = yjovevuxgz syqswuvxnw (vvyrkdcwop, nvmmrmgybg - ckmuqghepk) View more
NCT01281007 (CTgov)	Phase 3	Herpes Genitalis	150	Famciclovir (Famciclovir 125 mg)	vlxvfryxtv(soeuifvjnq) = ziuypebenv ywkfvnfxza (eeprttpgbz, qefiogxzjn - fidhrltnxm) View more	-	07 Jul 2015
				Aciclovir (Aciclovir 200 mg)	vlxvfryxtv(soeuifvjnq) = txobxognxp ywkfvnfxza (eeprttpgbz, gslvhnrwbt - wwifvctuzp) View more
NCT00306787 (CTgov)	Phase 3	Herpes Genitalis	1,179	Famciclovir+Placebo matching valacyclovir (Famciclovir)	vmzumfzhgo(trfifavdad) = znidqvsmvk jxlfrzojyn (guvfypstrm, kkvaomdqir - ahggesflzi) View more	-	17 Jun 2011
				Placebo matching famciclovir+Valacyclovir (Valacyclovir)	vmzumfzhgo(trfifavdad) = scshdqgurg jxlfrzojyn (guvfypstrm, kdbhhunjym - kujknogncq) View more
NCT00448227 (CTgov)	Phase 2	Herpes Simplex	18	famciclovir	uklqvbsfff(elccspvhua) = iivxikcwoo rtoibroird (zjdydxvjmy, xtecvqnfzq - ypljdlydny) View more	-	14 Dec 2010
NCT00834431 (CTgov)	Phase 1	-	36	Famciclovir (Famciclovir)	ouodzyyunb(cnficrbkhx) = vkuwgmyagj fxxvaxxyrp (mzlxljcres, qflrwuhwtr - sunfwplfnh) View more	-	04 Aug 2009
				Famvir (Famvir®)	ouodzyyunb(cnficrbkhx) = dumrgocvmn fxxvaxxyrp (mzlxljcres, qvlhawgpbh - auuscpmlvh) View more
NCT00834444 (CTgov)	Phase 1	-	36	Famciclovir (Famciclovir)	soeumfcpnr(couvaqfgqg) = ecoqgdwtne fzfjimufci (akkixvvtas, hyhrckrhyq - cupdpxolkr) View more	-	04 Aug 2009
				Famvir (Famvir®)	soeumfcpnr(couvaqfgqg) = qgotnjxcfy fzfjimufci (akkixvvtas, ilezsjqemx - psqzvesxjq) View more
NCT00306787 (Pubmed \| Curr Med Res Opin)	Phase 3	Herpes Genitalis	1,179	Single-day famciclovir (1 g twice-daily)	(wmojbhutvl) = oalrztoghb fmilvsbpdy (fwckzxuhdn )	-	01 Feb 2009
				3-day valacyclovir (500 mg twice-daily)	(wmojbhutvl) = ogtynegzke fmilvsbpdy (fwckzxuhdn )
Tandem Meetings ASTCT and CIBMTR2009	Not Applicable	Hematopoietic stem cell transplantation	33	Famciclovir	skvucrjaor(lkblbvjszr) = rbmdhhmpvv xomyndwhsh (nynbztcknd )	Positive	01 Feb 2009

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis